A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-11-28
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-12 (study day 6); relationship: N
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-23 (study day 17); relationship: not assessed
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-09 (study day 34); relationship: not assessed
Data queries
No data queries.